We are live on ! Find out more
IDIX

IDENIX PHARMACEUTICALS INC
IDIX

Delisted

IDIX was delisted on the 5th of August, 2014.

88 hedge funds and large institutions have $628M invested in IDENIX PHARMACEUTICALS INC in 2013 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

198% more call options, than puts

Call options by funds: $7.92M | Put options by funds: $2.65M

20% more capital invested

Capital invested by funds: $521M → $628M (+$106M)

10% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 31

5% less funds holding

Funds holding: 9388 (-5)

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

Holders
88
Holders Change
-5
Holders Change %
-5.38%
% of All Funds
2.55%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
13
Increased
28
Reduced
31
Closed
18
Calls
$7.92M
Puts
$2.65M
Net Calls
+$5.26M
Net Calls Change
+$340K
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$393K -$172K -37,237 -36%
Deutsche Bank
52
Deutsche Bank
Germany
$391K -$399K -86,317 -57%
WAM
53
Wolverine Asset Management
Illinois
$348K +$202K +43,600 +297%
Grantham, Mayo, Van Otterloo & Co (GMO)
54
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$335K +$160K +34,500 +160%
Goldman Sachs
55
Goldman Sachs
New York
$308K -$96.4K -20,841 -29%
Barclays
56
Barclays
United Kingdom
$301K +$187K +40,425 +204%
EWM
57
Edge Wealth Management
New York
$299K +$231K +50,000 New
UBS AM
58
UBS AM
Illinois
$290K +$7.4K +1,600 +3%
Citigroup
59
Citigroup
New York
$252K +$65.7K +14,207 +51%
BG
60
BlackRock Group
United Kingdom
$247K
PPA
61
Parametric Portfolio Associates
Washington
$244K +$17.8K +3,856 +10%
Allianz Asset Management
62
Allianz Asset Management
Germany
$209K +$50.9K +11,000 +46%
WMSA
63
Weiss Multi-Strategy Advisers
New York
$203K +$157K +34,000 New
AWS
64
Aris Wealth Services
Pennsylvania
$179K
TAM
65
Taurus Asset Management
New York
$179K
Verition Fund Management
66
Verition Fund Management
Connecticut
$94K +$73K +15,781 New
Creative Planning
67
Creative Planning
Kansas
$90K +$69.4K +15,000 New
SCA
68
SAC Capital Advisors
Connecticut
$83K +$64.3K +13,900 New
WFM
69
Wilmington Funds Management
Delaware
$81K -$74.6K -16,119 -54%
LTFS
70
Ladenburg Thalmann Financial Services
Florida
$81K +$62.5K +13,500 New
Prudential Financial
71
Prudential Financial
New Jersey
$78K -$1.39K -300 -2%
T
72
TradeWorx
New Jersey
$74K +$57.3K +12,376 New
EWM
73
Evercore Wealth Management
New York
$71K
RHBC
74
R.H. Bluestein & Co
Michigan
$69K -$102K -22,000 -66%
Dimensional Fund Advisors
75
Dimensional Fund Advisors
Texas
$68K

IDIX Hedge Fund Activity: Q4 2013 in Review

88 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in IDENIX PHARMACEUTICALS INC (IDIX) for Q4 2013, worth a combined $628M — up 20% from $521M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of IDIX and 13 opened new positions — a net loss of 5 holders — while 31 trimmed existing stakes and 28 added.

The largest buyer was Baupost Group, adding an estimated $33.5M. The largest seller was Bridger Management, cutting an estimated $9.77M.

  • 88 institutional investors held IDENIX PHARMACEUTICALS INC (IDIX) as of Q4 2013, down from 93 in Q3 2013.
  • Funds reported $628M of IDENIX PHARMACEUTICALS INC stock for Q4 2013, up 20% quarter-over-quarter.
  • 13 funds opened new IDENIX PHARMACEUTICALS INC positions in Q4 2013 and 18 closed out, a net change of -5 holders.
  • The largest IDENIX PHARMACEUTICALS INC buyer in Q4 2013 was Baupost Group, an estimated $33.5M added.
  • The largest IDENIX PHARMACEUTICALS INC seller in Q4 2013 was Bridger Management, an estimated $9.77M sold.

Based on aggregated 13F filings for Q4 2013.